Cancers' Sweet Tooth May Be Weakness
The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered. view more (2009-11-19)
Boron-based compounds trick a biomedical protein
Chemists and biologists have successfully demonstrated that specially synthesized boron compounds are readily accepted in biologically active enzymes, a move that, they say, is a proof of concept that could lead to new drug design strategies. view more (2009-09-03)
Mayo Clinic Proceedings: Common blood disorder may not be linked to as many serious diseases
A symptomless blood disorder, monoclonal gammopathy of undetermined significance, known as MGUS, is not linked to as many serious diseases as previously thought. view more (2009-08-26)
New study suggests possible genetic links between environmental toxins and multiple myeloma
The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today said newly published data may provide a possible genetic link between environmental toxins and bone disease in multiple myeloma. view more (2009-08-13)
Mayo researchers find race has role in incidence, survival of rare brain tumor
The incidence of a rare and deadly tumor called primary central nervous system lymphoma (PCNSL) is two times higher in black Americans, ages 20 to 49, than in white Americans, according to a Mayo Clinic study published in the June issue of Journal of Neuro-Oncology. view more (2009-07-31)
Individuals who apply pesticides are found to have double the risk of blood disorder
A study involving 678 individuals who apply pesticides, culled from a U.S. Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one's risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general... view more... (2009-06-15)
X-rays help predict permanent bone damage from bisphosphonates
Breast cancer patients, individuals at risk for osteoporosis and those undergoing certain types of bone cancer therapies often take drugs containing bisphosphonates. view more (2009-05-08)
Getting down to cancer basics
Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes. The new example - a gene on the X chromosome called UTX - is found in 10% of cases of multiple myeloma and 8% of esophageal cancers. view more (2009-03-30)
Search reveals molecules that block Stat 3
Finding molecules that block the activity of the oncogene Stat3 (signal transducer and activator of transcription) required screening literally millions of compounds, using computers that compared the structure of the cancer-causing gene to those of the small molecules, said a Baylor College of Medicine researcher in a report that appears in the... view more... (2009-03-11)
Protein helps immune cells to divide and conquer
Researchers at the University of California, San Diego School of Medicine have identified a key protein that is required for immune cells called B lymphocytes to divide and replicate themselves. The rapid generation of large numbers of these immune cells is critical to the body's antibody defense mechanism. view more (2009-03-09)
USC study finds that green tea blocks benefits of cancer drug
Contrary to popular assumptions about the health benefits of green tea, researchers at the University of Southern California (USC) have found that the widely used supplement renders a cancer drug used to treat multiple myeloma and mantle cell lymphoma completely ineffective in treating cancer. view more (2009-02-04)
Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds
An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky. They found that within 24 hours, 76 percent of leukemia cells had died after being exposed to the extract. view more (2009-01-05)
Cancer drug effectively treats transplant rejections
University of Cincinnati (UC) researchers have discovered a new therapy for transplant patients, targeting the antibody-producing plasma cells that can cause organ rejection. view more (2008-12-29)
Promising results from 2 trials highlighting pomalidomide presented at ASH
Celgene International Sarl (Nasdaq: CELG) today announced that its next IMiDs compound, pomalidomide, has shown promising activity with manageable safety and tolerability for the treatment of relapsed/refractory multiple myeloma (MM) and myelofibrosis. view more (2008-12-11)
Analysis shows revlimid plus dexamethasone increases overall survival in multiple myeloma patients
Celgene International Sarl (NASDAQ: CELG) announced that data from a landmark analysis of patients with relapsed/refractory multiple myeloma found that continuous treatment with REVLIMID (lenalidomide) in combination with dexamethasone after achieving best response resulted in significantly longer overall survival and increased time to disease... view more... (2008-12-11)
Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology. view more (2008-12-10)
Race a factor in receiving transplant treatment for bone marrow cancer but does not affect outcomes
A new study by researchers at The Medical College of Wisconsin Cancer Center Milwaukee, has found that African Americans and whites have identical survival rates after undergoing autologous (self donor) bone marrow transplant treatment for a common cancer of the bone marrow (multiple myeloma). view more (2008-12-09)
Lenalidomide safe as single therapy for elderly CLL patients
The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology. view more (2008-12-08)
On the trail of a targeted therapy for blood cancers
nvestigators from the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine are focusing on a family of blood proteins that they hope holds a key to decreasing the toxic effects of chemotherapy in children and adults. view more (2008-10-13)
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. view more (2008-10-07)
|
|
